Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 330 followers
Latest posts
Last updated 33 minutes ago
EMA risk management information day, European Medicines Agency, Amsterdam, the Netherlands, from 8 September 2026, 09:00 (CEST) to 8 September 2026, 17:00 (CEST)
about 1 hour ago
EMA risk management information day, European Medicines Agency, Amsterdam, the Netherlands, from...
Highlights from the second expert panels and notified bodies workshop, Online, 23 May 2025
about 1 hour ago
Highlights from the second expert panels and notified bodies workshop, Online, 23...
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - March 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 10 March 2026, 15:00 (CET) to 10 March 2026, 16:00 (C
about 2 hours ago
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and...
Annex to agenda of the CHMP meeting 18-21 May 2026
about 2 hours ago
Annex to agenda of the CHMP meeting 18-21 May 2026
Agenda of the CHMP meeting 18-21 May 2026
about 2 hours ago
Agenda of the CHMP meeting 18-21 May 2026
Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 8, Status: Authorised
about 2 hours ago
Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of...
Orphan designation: orvepitant maleate Treatment of idiopathic pulmonary fibrosis, 21/11/2025 Withdrawn
about 3 hours ago
Orphan designation: orvepitant maleate Treatment of idiopathic pulmonary fibrosis, 21/11/2025 Withdrawn
Orphan designation: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide Treatment of congenital hyperinsulinism, 09/12/2020 Withdrawn
about 3 hours ago
Orphan designation: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide Treatment of congenital hyperinsulinism, 09/12/2020 Withdrawn
Orphan designation: serplulimab Treatment of small cell lung cancer, 20/02/2025 Withdrawn
about 3 hours ago
Orphan designation: serplulimab Treatment of small cell lung cancer, 20/02/2025 Withdrawn
Orphan designation: Dexamethasone sodium phosphate encapsulated in human erythrocytes Treatment of cystic fibrosis, 20/10/2004 Withdrawn
about 3 hours ago
Orphan designation: Dexamethasone sodium phosphate encapsulated in human erythrocytes Treatment of cystic...
Orphan designation: Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes Treatment of ataxia telangiectasia, 17/07/2013 Withdrawn
about 3 hours ago
Orphan designation: Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes Treatment of...
Orphan designation: tazemetostat Treatment of diffuse large B-cell lymphoma, 21/03/2018 Withdrawn
about 3 hours ago
Orphan designation: tazemetostat Treatment of diffuse large B-cell lymphoma, 21/03/2018 Withdrawn